FDA working on a 'dozen' policies to boost copycat biotech drugs

NEW YORK (Reuters) – The U.S. Food & Drug Administration is working on around a dozen actions to boost use of cheaper versions of expensive biotech medicines, the head of the agency Scott Gottlieb said on Wednesday.

Source: Reuters Medical News